Krystal Biotech (NASDAQ: KRYS)
Krystal Biotech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Krystal Biotech Company Info
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
News & Analysis
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Have investors already missed the boat with this stock?
Up 48% in 2023, Is This Biotech Stock a Buy?
How much longer can this biotech's run last?
Why Shares of Krystal Biotech Are Rising Monday
The company is moving quickly to market its newly approved therapy.
2 Growth Stocks That Could Double in the Next Year
Just don't be too quick to press the buy button.
Can This Healthcare Stock Keep Beating the Market?
This biotech looks promising, but there are potential pitfalls to consider.
2 Biotech Stocks That Could Skyrocket This Year
For these two companies, the rewards could end up outweighing the risks.
Could This Soaring Biotech Stock Make You Rich?
This company has made quite a lot of noise recently.
Why Krystal Biotech's Shares Rose More Than 77% This Week
The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.